Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
PATTERN OF KRAS GENE EXPRESSION IN IRAQI WOMEN OVARIAN CARCINOMA.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jumaa Maysaa Ghazi
Аннотация
OBJECTIVE: The aim: The goal of this study was to detect if KRAS gene and levels of had any clinical significance in the ovarian cancer by measuring levels of KRAS mRNA.
PATIENTS AND METHODS: Materials and methods: The investigation was conducted on 84 tissue samples from newly diagnosed patients with ovarian cancer. Twenty-eight tissue sections with benign ovarian tumors were used as a control group. The qRT- PCR technique was used for measuring and analyzing levels of KRAS mRNA.
RESULTS: Results: Relative increasing of KRAS mRNA level in cancer samples was statistically significant (P<0.01) when compared to benign tumors. Statistically no significant differences were found between KRAS mRNA levels and menopausal status or family history. Gene expression has been substantially connected with age groups as the highest levels of KRAS mRNA was recorded in patients with age 50-74 years (P<0.01). Endometrium tumors exhibited significant correlations (P<0.01) across histopathological tumor types. In correlation with tumor stages, stage I was substantially linked compared to stage I (P<0.01).
CONCLUSION: Conclusions: It was concluded that over expression of the KRAS gene is linked to early stages of ovarian cancer, which implying that mRNA levels could be used as a diagnostic and predictive factor for ovarian cancer. More research with larger groups of ovarian cancer specimens in both primary and advanced stages is needed.
PATIENTS AND METHODS: Materials and methods: The investigation was conducted on 84 tissue samples from newly diagnosed patients with ovarian cancer. Twenty-eight tissue sections with benign ovarian tumors were used as a control group. The qRT- PCR technique was used for measuring and analyzing levels of KRAS mRNA.
RESULTS: Results: Relative increasing of KRAS mRNA level in cancer samples was statistically significant (P<0.01) when compared to benign tumors. Statistically no significant differences were found between KRAS mRNA levels and menopausal status or family history. Gene expression has been substantially connected with age groups as the highest levels of KRAS mRNA was recorded in patients with age 50-74 years (P<0.01). Endometrium tumors exhibited significant correlations (P<0.01) across histopathological tumor types. In correlation with tumor stages, stage I was substantially linked compared to stage I (P<0.01).
CONCLUSION: Conclusions: It was concluded that over expression of the KRAS gene is linked to early stages of ovarian cancer, which implying that mRNA levels could be used as a diagnostic and predictive factor for ovarian cancer. More research with larger groups of ovarian cancer specimens in both primary and advanced stages is needed.